Efficacy and safety of apremilast monotherapy for moderate to severe psoriasis: retrospective study

A Ighani, JR Georgakopoulos, LL Zhou… - Journal of …, 2018 - journals.sagepub.com
Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …
被引用次数：23 相关文章

Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study

A Ighani, JR Georgakopoulos, LL Zhou… - Journal of Cutaneous …, 2018 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Apremilast is a new oral drug
for the treatment of moderate to severe plaque psoriasis that reduces inflammation by …
[PDF] academia.edu

[PDF][PDF] Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study

A Ighani, JR Georgakopoulos, LL Zhou… - Journal of Cutaneous …, 2018 - academia.edu
Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.

A Ighani, JR Georgakopoulos, LL Zhou… - Journal of Cutaneous …, 2018 - europepmc.org
Background Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study

A Ighani, JR Georgakopoulos… - Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …